Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

UBS reaffirmed its Buy rating and $105 target for Merck, brushing off investor pessimism about the pharmaceutical giant’s ...

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

The high court sides with HHS on HIV PrEP drugs; Health Secretary RFK Jr.’s newly appointed CDC vaccine advisors discuss thimerosal in flu vaccines, skip vote on Moderna’s mRNA-based RSV vaccine; FDA ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

A medical panel appointed by Health Secretary Robert F. Kennedy Jr. voted Thursday to recommend a new preventive shot against ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in ...